The global retinopathy of prematurity therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing incidence of premature births and high prevalence of retinopathy in premature infants.
The global retinopathy of prematurity therapeutics market is segmented on the basis of type, application, and region. On the basis of type, it is classified into I09A0133 (Mecasermin Rinfabate), Propranolol, and 200 (Propranolol). On the basis of application, it is classified into hospital care and home care. On the basis of region, it includes North America (US, Canada), Latin America (Mexico), Europe (Germany), Asia Pacific & Middle East & Africa (India).
- The number of premature births is increasing globally, which will lead to an increase in the number of patients with retinopathy of prematurity.
- The global population is aging, which will lead to an increase in the number of patients with retinopathy of prematurity.
- There are new treatments for retinopathy of prematurity that are being developed and marketed, which will lead to an increase in the market size for retinopathy of prematurity therapeutics.
- There are new treatments for retinopathy of prematurity that are being developed and marketed, which will lead to a decrease in the market size for other therapies.
- The cost-effectiveness ratio for treatment options is high.
Industry Growth Insights published a new data on “Retinopathy Of Prematurity Therapeutics Market”. The research report is titled “Retinopathy Of Prematurity Therapeutics Market research by Types (IB-09A0133, Mecasermin Rinfabate, Propranolol, R-200, Others), By Applications (Hospital, Clinic, Home Care), By Players/Companies Biomar Microbial Technologies, D. Western Therapeutics Institute Inc, F. Hoffmann-La Roche Ltd, Insmed Inc, Recordati SpA”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Retinopathy Of Prematurity Therapeutics Market Research Report
By Type
IB-09A0133, Mecasermin Rinfabate, Propranolol, R-200, Others
By Application
Hospital, Clinic, Home Care
By Companies
Biomar Microbial Technologies, D. Western Therapeutics Institute Inc, F. Hoffmann-La Roche Ltd, Insmed Inc, Recordati SpA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Retinopathy Of Prematurity Therapeutics Market Report Segments:
The global Retinopathy Of Prematurity Therapeutics market is segmented on the basis of:
Types
IB-09A0133, Mecasermin Rinfabate, Propranolol, R-200, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Home Care
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biomar Microbial Technologies
- D. Western Therapeutics Institute Inc
- F. Hoffmann-La Roche Ltd
- Insmed Inc
- Recordati SpA
Highlights of The Retinopathy Of Prematurity Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- IB-09A0133
- Mecasermin Rinfabate
- Propranolol
- R-200
- Others
- By Application:
- Hospital
- Clinic
- Home Care
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Retinopathy Of Prematurity Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Retinopathy of prematurity (ROP) is a group of diseases that affect the retina, which is the layer of tissue at the back of your eye. ROP can cause vision problems, including blindness.
Some of the key players operating in the retinopathy of prematurity therapeutics market are Biomar Microbial Technologies, D. Western Therapeutics Institute Inc, F. Hoffmann-La Roche Ltd, Insmed Inc, Recordati SpA.
The retinopathy of prematurity therapeutics market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Retinopathy Of Prematurity Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Retinopathy Of Prematurity Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Retinopathy Of Prematurity Therapeutics Market - Supply Chain
4.5. Global Retinopathy Of Prematurity Therapeutics Market Forecast
4.5.1. Retinopathy Of Prematurity Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Retinopathy Of Prematurity Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Retinopathy Of Prematurity Therapeutics Market Absolute $ Opportunity
5. Global Retinopathy Of Prematurity Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Type
5.3.1. IB-09A0133
5.3.2. Mecasermin Rinfabate
5.3.3. Propranolol
5.3.4. R-200
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Retinopathy Of Prematurity Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Home Care
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Retinopathy Of Prematurity Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Retinopathy Of Prematurity Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Retinopathy Of Prematurity Therapeutics Demand Share Forecast, 2019-2026
9. North America Retinopathy Of Prematurity Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Home Care
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Type
9.7.1. IB-09A0133
9.7.2. Mecasermin Rinfabate
9.7.3. Propranolol
9.7.4. R-200
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Retinopathy Of Prematurity Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Retinopathy Of Prematurity Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Home Care
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Type
10.7.1. IB-09A0133
10.7.2. Mecasermin Rinfabate
10.7.3. Propranolol
10.7.4. R-200
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Retinopathy Of Prematurity Therapeutics Demand Share Forecast, 2019-2026
11. Europe Retinopathy Of Prematurity Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Home Care
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Type
11.7.1. IB-09A0133
11.7.2. Measermin Rinfabate
11.7.3. Propranolol
11.7.4. R-200
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Retinopathy Of Prematurity Therapeutics Demand Share, 2019-2026
12. Asia Pacific Retinopathy Of Prematurity Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Home Care
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Type
12.7.1. IB-09A0133
12.7.2. Mecasermin Rinfabate
12.7.3. Propranolol
12.7.4. R-200
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Retinopathy Of Prematurity Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Retinopathy Of Prematurity Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Home Care
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Retinopathy Of Prematurity Therapeutics Market Size and Volume Forecast by Type
13.7.1. IB-09A0133
13.7.2. Mecasermin Rinfabate
13.7.3. Propranolol
13.7.4. R-200
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Retinopathy Of Prematurity Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Retinopathy Of Prematurity Therapeutics Market: Market Share Analysis
14.2. Retinopathy Of Prematurity Therapeutics Distributors and Customers
14.3. Retinopathy Of Prematurity Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Biomar Microbial Technologies
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. D. Western Therapeutics Institute Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. F. Hoffmann-La Roche Ltd
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Insmed Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Recordati SpA
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
